Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress…